Correlation between gastrointestinal hormones and anxiety‑depressive states in irritable bowel syndrome

Han,Baojuan

doi:10.3892/etm.2013.1211

Correlation between gastrointestinal hormones and anxiety‑depressive states in irritable bowel syndrome

Authors:
- Baojuan Han
View Affiliations

Affiliations: Department of Gastroenterology, Xingtai People's Hospital, Xingtai, Hebei 054031, P.R. China
Published online on: July 9, 2013 https://doi.org/10.3892/etm.2013.1211
Pages: 715-720

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the mechanism(s) of action of gastrointestinal hormones in the pathogenesis of irritable bowel syndrome (IBS), and the correlation between gastrointestinal hormones and psychological factors. Patients with IBS were divided into IBS with normal emotional state ratings and IBS in anxiety‑depressive states groups. The two groups were then subdivided into IBS‑constipation predominant (IBS‑C) and IBS‑diarrhea predominant (IBS‑D) groups. Non‑IBS patients with normal depression and anxiety ratings were recruited as controls. The serum concentrations of somatostatin (SS) and vasoactive intestinal peptide (VIP) were measured by radioimmunoassay, and the expression of SS and VIP in the colonic mucosa was detected by immunohistochemistry and radioimmunoassay. The anxiety‑depression scores of patients with IBS were significantly different from those of the control group (P<0.05). The expression levels of SS and VIP in the serum and colonic mucosa of the patients with IBS were higher compared with those of the control group. Furthermore, the expression level of SS in the IBS‑C group demonstrated a significantly larger increase than that in the IBS‑D group (P<0.05); however, there was no significant difference in the expression of VIP between the IBS‑C and IBS‑D groups (P>0.05). In addition, the expression levels of SS and VIP in the IBS groups with normal emotional state ratings were notably different from those in the IBS groups in anxiety‑depressive states (P<0.05). Anxiety‑depressive states may lead to changes in the secretion of SS and VIP, and subsequently to changes in gastrointestinal motility and function.

View Figures

View References

1	Olden KW and Schuster MM: Irritable bowel syndrome. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Feldman M, Scharschmidt BF and Sleisenger MH: W.B. Saunders Co; Philadelphia: pp. 1536–1547. 1998
2	Kanazawa M, Hongo M and Fukudo S: Visceral hypersensitivity in irritable bowel syndrome. J Gastroenterol Hepatol. 26(Suppl 3): 119–121. 2011. View Article : Google Scholar
3	Zhao Y, Ke M, Wang Z, Wei J, Zhu L, Sun X and Zhang J: Pathophysiplogical and psychosocial study in patients with functional vomiting. J Neurogastroenterol Motil. 16:274–280. 2010. View Article : Google Scholar : PubMed/NCBI
4	Zung WW: A self-rating depression scale. Arch Gen Psychiatry. 12:63–70. 1965. View Article : Google Scholar : PubMed/NCBI
5	Zung WW: A rating instrument for anxiety disorders. Psychosomatics. 12:371–379. 1971. View Article : Google Scholar : PubMed/NCBI
6	Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F and Spiller RC: Functional bowel disorders. Gastroenterology. 130:1480–1491. 2006. View Article : Google Scholar : PubMed/NCBI
7	Fishbain D: Evidence-based data on pain relief with antidepressants. Ann Med. 32:305–316. 2000. View Article : Google Scholar : PubMed/NCBI
8	Caso JR, Leza JC and Menchén L: The effects of physical and psychological stress on the gastro-intestinal tract: lessons from animal models. Curr Mol Med. 8:299–312. 2008. View Article : Google Scholar : PubMed/NCBI
9	Crowell MD, Harris L, Jones MP and Chang L: New insights into the pathophysiology of irritable bowel syndrome: implications for future treatments. Curr Gastroenterol Rep. 7:272–279. 2005. View Article : Google Scholar : PubMed/NCBI
10	Binimelis J, Webb SM and Monés J: Somatostatin and irritable bowel syndrome. Lancet. 2:15331987. View Article : Google Scholar : PubMed/NCBI
11	Wouters MM and Boeckxstaens GE: Neuroimmune mechanisms in functional bowel disorders. Neth J Med. 69:55–61. 2011.PubMed/NCBI
12	Spiller R: Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil. 19(Suppl 2): 25–31. 2007. View Article : Google Scholar : PubMed/NCBI
13	Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S and Jones M: Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci. 53:108–115. 2008. View Article : Google Scholar : PubMed/NCBI
14	Camilleri M and Fealy RO: Idiopathic autonomic denervation in eight patients presenting with functional gastrointestinal disease: A causal association? Dig Dis Sci. 35:609–616. 2008. View Article : Google Scholar
15	Smart HL and Atkinson M: Abnormal vagal function in irritable bowel syndrome. Lancet. 2:475–478. 1987. View Article : Google Scholar : PubMed/NCBI
16	Ringel Y, Sperber AD and Drossman DA: Irritable bowel syndrome. Annu Rev Med. 52:319–338. 2001. View Article : Google Scholar : PubMed/NCBI
17	Simrén M, Abrahamsson H and Björnsson ES: An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut. 48:20–27. 2001.
18	Liebregts T, Adam B, Bredack C, et al: Immune activation in patients with irritable bowel syndrome. Gastroenterology. 132:913–920. 2007. View Article : Google Scholar : PubMed/NCBI
19	Drossman DA: Brain imaging and its implications for studying centrally targeted treatments in irritable bowel syndrome: a primer for gastroenterologists. Gut. 54:569–573. 2005. View Article : Google Scholar : PubMed/NCBI
20	Gonçalves L, Almeida A and Pertovaara A: Pronociceptive changes in response properties of rostroventromedial medullary neurons in a rat model of peripheral neuropathy. Eur J Neurosci. 26:2188–2195. 2007.PubMed/NCBI
21	Spence MJ and Moss-Morris R: The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis. Gut. 56:1066–1071. 2007. View Article : Google Scholar
22	Ladep NG, Obindo TJ, Audu MD, Okeke EN and Malu AO: Depression in patients with irritable bowel syndrome in Jos, Nigeria. World J Gastroenterol. 12:7844–7847. 2006.PubMed/NCBI
23	Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ and Hutchinson IV: Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut. 52:91–93. 2003. View Article : Google Scholar : PubMed/NCBI
24	Holsboer F: The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 23:477–501. 2000. View Article : Google Scholar : PubMed/NCBI
25	Kronfol Z and Remick DG: Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 157:683–694. 2000. View Article : Google Scholar : PubMed/NCBI